

News event

15 August 2019

OnDosis awarded Horizon 20/20 funding and attending key meetings to broaden partnerships

During the first half of 2019 OnDosis was awarded a European Union's Horizon 2020 Research and Innovation Programme SME (Small and Medium-sized Enterprises) instrument for phase 1. This is part of the Horizon 2020 Framework Programme which funds high-potential and high-risk innovation for companies with breakthrough ideas. This will help OnDosis progress the work in developing its product for ADHD. Supporting its connectivity interface OnDosis has also been contracted by a EUREKA cluster 5G project. Upcoming events where OnDosis will be present include LSX Nordics Congress in Stockholm 28-29 August and European Pediatric Formulation Initiative Congress (EuPFI) in Malmo during September.

About OnDosis

Swedish life science company OnDosis has developed a proprietary technology to deliver flexible and individualised dosing of oral medicines. By integrating medicines with intelligent dosing and digital capabilities in a handheld device, OnDosis offers a new way to take oral medicines – in micro units. Individualised, intuitive and connected. Initial focus areas are pain, ADHD and immunosuppression. OnDosis is a spin-out from AstraZeneca and headquartered in Gothenburg, Sweden. More information at www.ondosis.com

Follow us on [LinkedIn](#)

Postal address

OnDosis AB, Erik Dahlbergsgatan 11 A
41126 Göteborg, Sweden

Visiting address

OnDosis AB, AstraZeneca BioVentureHub
Pepparedsleden 1, 431 50 Mölndal, Sweden